Opko Health layoffs, on the record

Headcount, as reported

Job cuts, severance and restructuring

1. Our summaryCost of revenue for 2022 included severance costs from reductions in the workforce. year ended December 31, 2022 · Cost: $6.1 million in severance costs

   Word for word“Cost of revenue for the year ended December 31, 2022, included $6.1 million in severance costs resulting from reductions in our workforce.” 10-K for 2023

2. Our summarySG&A expenses increased mainly due to severance charges tied to cost reduction initiatives, partly offset by BioReference cost-reduction efforts that included a reduction in employee headcount. Cost: $26.3 million in severance charges

   Word for word“The increase in expense is primarily related to $26.3 million in severance charges associated with cost reduction initiatives and $9.7 million in adjustments to the life of certain leases.” 10-K for 2024

3. Our summaryContinued cost-reduction initiatives at BioReference included a reduction in employee headcount and the streamlining of certain smaller operations.

   Word for word“This was partially offset by continued cost-reduction initiatives at BioReference, which included a reduction in employee headcount and the streamlining of certain smaller operations, resulting in an overall decrease in employee-related expenses and other operating efficiencies.” 10-K for 2024

4. Our summaryEmployee severance was recorded as a long-term accrued liability on the balance sheet.

   Word for word“Other long-term liabilities: Employee severance $ 14,269 $ — Mortgages and other debts payable 3,002 7,709 Finance leases long-term 4,064 7,274 Contract liabilities 6 7 Other 11,497 12,199 $ 32,838 $ 27,189 Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen, BioReference and ModeX.” 10-K for 2024

5. Our summaryThe company cut its BioReference workforce after restructurings and closed laboratory facilities in several states. as of December 31, 2025 · Affected: approximately 1,373 full-time employees as of December 31, 2025, down from approximately 3,300

   Word for word“We have also reduced our BioReference workforce to approximately 1,373 full-time employees as of December 31, 2025, down from approximately 3,300 prior to the restructurings.” 10-K for 2025

Opko Health has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.

Read from Opko Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.